Latest news
NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingViewTradingView · Thu, 06 Aug 2026 20:35:16 GMTNXTC: Merger with Avere and $320M financing announced as net loss narrows on reduced expenses - TradingViewTradingView · Thu, 06 Aug 2026 20:32:02 GMTNXTC: Merger agreement with Avere Therapeutics drives restructuring, cost cuts, and asset divestitures - TradingViewTradingView · Thu, 06 Aug 2026 20:28:58 GMTNextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock TitanStock Titan · Thu, 06 Aug 2026 20:26:26 GMTNextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock TitanStock Titan · Thu, 06 Aug 2026 20:17:25 GMTNextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:13:40 GMTNextCure - The Pharma LetterThe Pharma Letter · Wed, 05 Aug 2026 13:34:21 GMTNextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4 - Stock TitanStock Titan · Tue, 04 Aug 2026 11:35:04 GMT